Androgen-receptor splice variant-7-positive prostate cancer: a novel molecular subtype with markedly worse androgen-deprivation therapy outcomes in newly diagnosed patients
Authors:
Open Access
- 1 January 2018
- journal article
- research article
- Published by Elsevier in Laboratory Investigation
- Vol. 31 (1) , 198-208
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 32016
- Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor CellsEuropean Urology, 2015
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate CancerNew England Journal of Medicine, 2014
- Breast cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer MetastasesPLOS ONE, 2011
- Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptorProceedings of the National Academy of Sciences, 2010
- Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variantJournal of Clinical Investigation, 2010
- Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletionNature Reviews Endocrinology, 2009
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Studies on Prostatic Cancer: I. The Effect of Castration, Of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the ProstateCA: A Cancer Journal for Clinicians, 1972